CaRCinOma DeLLa PROstata - Osservatorio Nazionale Screening

lg carcinoma della prostata--Scattoni V, Roscigno M, Freschi M, et al. Predictors of prostate cancer after initial diagnosis of atypicalsmall acinar proliferation at 10 to 12 core biopsies. Urology 2005; 66: 1043-7.--Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamidein combined androgen blockade for patients with advanced prostatic carcinoma: final report of a doubleblind,randomized, multicenter trial. Casodex Combination Study Group. Urology 1997; 50: 330-6.--Schild SE, Wong WW, Novicki DE, Ferrigni RG, Swanson SK. Detection of residual prostate cancer afterradical prostatectomy with the Abbott IMx PSA assay. Urology 1996; 47: 878-81.--Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostatecancer. Cochrane Database Syst Rev. 2000; (2).--Schöder FH (a), Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. SeminNucl Med 2004; 34: 274-92.--Schröder FH (b), Kurth KH, Fosså SD, et al. Members of the European Organisation for the Research andTreatment of Cancer Genito-urinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostatecancer without local treatment of the primary tumor: results of European Organisation for the Researchand Treatment of Cancer 30846--a phase III study. J Urol 2004; 172: 923-7.--Schröder FH, Hugosson J, Roobol MJ, for the ERSPC Investigators. Screening and Prostate-Cancer Mortalityin a Randomized European Study. N Engl J Med 2009; 360: 1320-8.--Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostatecancer in pre-screened populations? Eur Urol 2006; 49: 460-5.--Sehdev AE, Pan CC, Epstein JI. Comparative analysis of sampling methods for grossing radical prostatectomyspecimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Hum Pathol 2001; 32: 494-9.--Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advancedprostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77.--Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localisedprostate cancer. Health Technol Assess 1997; 1: 1-96.--Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of basal cell cocktail (34betaE12+ p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol 2004; 122: 517-23.--Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostatecancer. N Engl J Med 2005; 352: 154-64.--Sharkey J, Cantor A, Solc Z, et al. Brachytherapy versus radical prostatectomy in patients with clinicallylocalized prostate cancer. Curr Urol Rep 2002; 3: 250-7.--Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J Urol 2006;176: S66-71.--Smith JA, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ. Transrectal ultrasound versusdigital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutionaltrial. J Urol 1997; 157: 902-6.--Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivationtherapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.--Sölétormos G, Semjonow A, Sibley PE, et al. Biological variation of total prostate-specific antigen: a surveyof published estimates and consequences for clinical practice. Clin Chem 2005; 51: 1342-51.--Sonnad SS, Langlotz CP, Schwartz JS. Accuracy of MR imaging for staging prostate cancer: a metaanalysisto examine the effect of technologic change. Acad Radiol 2001; 8: 149-57.--Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The prevalence of prostate carcinoma and itsprecursor in Hungary: an autopsy study. Eur Urol 2005; 48: 739-44.--Southwick PC, Catalona WJ, Partin AW, et al. Prediction of post-radical prostatectomy pathological outcomefor stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenterclinical trial. J Urol 1999; 162: 1346-51.--Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positivesentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005; 12: 654-9.--Srigley JR, Amin MB, Epstein JI, et al. Updated protocol for the examination of specimens from patientswith carcinoma of the prostate gland. Arch Pathol Lab Med 2006; 130: 936-46.140